On February 12, 2026 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, reported the availability of PanTracer Pro, a new addition to the PanTracer Family, designed to help clinicians navigate increasingly complex molecular testing workflows to make informed decisions for patients with advanced-stage solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As precision oncology continues to evolve, clinicians face growing diagnostic complexity, increasing biomarker requirements, and mounting pressure to initiate treatment quickly, often before a complete molecular profile is available. Fragmented testing workflows, sequential ordering, and tissue limitations can delay care and introduce uncertainty at critical decision points. PanTracer Pro was developed to address these challenges more comprehensively and earlier in the diagnostic pathway.
"Every delay or unanswered question in the diagnostic process can affect how quickly patients begin treatment," said Tony Zook, chief executive officer at NeoGenomics. "PanTracer Pro is designed to help clinicians get the information they need earlier and more reliably, so care teams can plan next steps with greater clarity and confidence across the care journey."
PanTracer Pro integrates broad, comprehensive genomic profiling (CGP) with diagnosis-directed immunohistochemistry (IHC) and ancillary testing selected based on tumor type. By delivering comprehensive, guideline-aligned insights through a single coordinated order, PanTracer Pro enables physicians to ensure relevant biomarkers are assessed upfront rather than through multiple, sequential tests. Turnaround time for the test is 8–10 days, supporting timely real-world treatment decisions.
Beyond streamlining test selection, PanTracer Pro may help identify clinically relevant biomarkers that can be missed with incomplete testing. The ability of PanTracer Pro to combine broad DNA and RNA sequencing across more than 500 cancer-related genes with tumor-specific ancillary testing supports therapy selection, helps identify potential clinical trial options, and facilitates personalized treatment planning based on a patient’s unique tumor biology. When tissue samples are insufficient or unavailable, cases can automatically reflex to PanTracer LBx, NeoGenomics’ pan-solid tumor liquid biopsy assay, allowing clinicians to continue diagnostic workup without restarting the process.
(Press release, NeoGenomics Laboratories, FEB 12, 2026, View Source [SID1234662657])